Study identifier:D7670C00001
ClinicalTrials.gov identifier:NCT06084884
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA
Hepatocellular Carcinoma
Phase 1/2
No
-
All
94
Interventional
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jul 2025 by AstraZeneca
AstraZeneca
-
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
This first-time in human, single-arm, open-label multicentre Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.
Location
Location
New York, NY, United States, 10065
Location
Hackensack, NJ, United States, 07601
Location
Rochester, MN, United States, 55905
Location
Duarte, CA, United States, 91010
Location
Westwood, KS, United States, 66205
Location
Philadelphia, PA, United States, 19104
Location
Columbus, OH, United States, 43210
Location
Washington, DC, United States, 20007
Arms | Assigned Interventions |
---|---|
Experimental: AZD5851 Subjects will receive AZD5851 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide). | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.